Antiretroviral Treatment of Human Immunodeficiency Virus Infection: Swedish Recommendations

References

• Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society – USA Panel. JAMA 2002; 288: 222–35.
   Google Scholar
• US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. http://www.hivatis.org/ (4 February 2002).
   Google Scholar
• Robbins G, Shafer R, Smeaton L, De Gruttola V, Pettinelli C, Snyder S, et al., for the ACTG Team. Antiretroviral strategies in treatment naive HIV + subjects. (ACTG 384) XIV International AIDS Conference, 2002. LbOr20A and B.
   Google Scholar
• Krolewiecki AJ, Bouzas MB, Cahn P, Cassetti I, Zala C, Gun A, et al. Treatment discontinuation in patients who started antiretroviral therapy following the 1996 IAS–USA recommendations. A prospective randomized trial. XIV International AIDS Conference, 2002. ThOrB1440.
   Google Scholar
• Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30 (Suppl 2): S171–6.
   PubMed Web of Science ®Google Scholar
• Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS 1999; 13: 1677–85.
   Google Scholar
• Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9–F14.
   Google Scholar
• Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186: 189–97.
   PubMed Web of Science ®Google Scholar
• van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001; 6: 201–29.
   PubMed Web of Science ®Google Scholar
• Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al. Swiss HIV Cohort Study. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251–60.
   Google Scholar
• Flandre P, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, et al. Final analysis of the Trilege induction–maintenance trial: results at 18 months. AIDS 2002; 16: 561–8.
   Google Scholar
• Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 1517–26.
   PubMed Web of Science ®Google Scholar
• Lindback S, Brostrom C, Karlsson A, Gaines H. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 × 106/l, AIDS, and death from AIDS? Br Med J 1994; 309: 1535–7.
   PubMed Web of Science ®Google Scholar
• Hoen B, Dumon B, Harzic M, Venet A, Dubeaux B, Lescoux C, et al. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. J Infect Dis 1999; 180: 1342–6.
   PubMed Web of Science ®Google Scholar
• Updated US Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV,, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep 2001; 50(RR-11): 1–52.
   Google Scholar
• Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946–54.
   PubMed Web of Science ®Google Scholar
• Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385–94.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999; 179: 1375–81.
   PubMed Web of Science ®Google Scholar
• Lederman MM. Immune restoration and CD4 + T-cell function with antiretroviral therapies. AIDS 2001; 15 (Suppl 2): S11–5.
   Google Scholar
• Palella FJ Jr, Chmiel JS, Moorman AC, Holmberg SD, HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16: 1617–26.
   Google Scholar
• Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195.
   PubMed Web of Science ®Google Scholar
• Birk M, Svedhem V, Sonnerborg A. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 2001; 15: 1359–68.
   Google Scholar
• Acostas EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002; 18: 825–34.
   Google Scholar
• Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863–8.
   Google Scholar
• Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209–18.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chrisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093–9.
   PubMed Web of Science ®Google Scholar